141 related articles for article (PubMed ID: 23351040)
1. How do metabolites differ from their parent molecules and how are they excreted?
Kirchmair J; Howlett A; Peironcely JE; Murrell DS; Williamson MJ; Adams SE; Hankemeier T; van Buren L; Duchateau G; Klaffke W; Glen RC
J Chem Inf Model; 2013 Feb; 53(2):354-67. PubMed ID: 23351040
[TBL] [Abstract][Full Text] [Related]
2. Expanding the medicinally relevant chemical space with compound libraries.
López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
[TBL] [Abstract][Full Text] [Related]
3. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
4. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
[TBL] [Abstract][Full Text] [Related]
5. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
Dobson PD; Patel Y; Kell DB
Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
[TBL] [Abstract][Full Text] [Related]
6. Chemicalome and metabolome matching approach to elucidating biological metabolic networks of complex mixtures.
Gong P; Cui N; Wu L; Liang Y; Hao K; Xu X; Tang W; Wang G; Hao H
Anal Chem; 2012 Mar; 84(6):2995-3002. PubMed ID: 22356250
[TBL] [Abstract][Full Text] [Related]
7. Mapping human metabolic pathways in the small molecule chemical space.
Macchiarulo A; Thornton JM; Nobeli I
J Chem Inf Model; 2009 Oct; 49(10):2272-89. PubMed ID: 19795883
[TBL] [Abstract][Full Text] [Related]
8. Correlative analysis of metabolite profiling of Danggui Buxue Tang in rat biological fluids by rapid resolution LC-TOF/MS.
Li CY; Qi LW; Li P
J Pharm Biomed Anal; 2011 Apr; 55(1):146-60. PubMed ID: 21277133
[TBL] [Abstract][Full Text] [Related]
9. [Strategy of molecular design of drugs: the unification of macro-properties and micro-structures of a molecule].
Guo ZR
Yao Xue Xue Bao; 2008 Mar; 43(3):227-33. PubMed ID: 18630256
[TBL] [Abstract][Full Text] [Related]
10. Understanding the transport properties of metabolites: case studies and considerations for drug development.
Zamek-Gliszczynski MJ; Chu X; Polli JW; Paine MF; Galetin A
Drug Metab Dispos; 2014 Apr; 42(4):650-64. PubMed ID: 24346835
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy.
Obach RS
Pharmacol Rev; 2013 Apr; 65(2):578-640. PubMed ID: 23406671
[TBL] [Abstract][Full Text] [Related]
12. Physiochemical property space distribution among human metabolites, drugs and toxins.
Khanna V; Ranganathan S
BMC Bioinformatics; 2009 Dec; 10 Suppl 15(Suppl 15):S10. PubMed ID: 19958509
[TBL] [Abstract][Full Text] [Related]
13. Characterization of metabolites of tanshinone IIA in rats by liquid chromatography/tandem mass spectrometry.
Li P; Wang GJ; Li J; Hao HP; Zheng CN
J Mass Spectrom; 2006 May; 41(5):670-84. PubMed ID: 16598708
[TBL] [Abstract][Full Text] [Related]
14. Compound optimization through data set-dependent chemical transformations.
de la Vega de León A; Bajorath J
J Chem Inf Model; 2013 Jun; 53(6):1263-71. PubMed ID: 23654345
[TBL] [Abstract][Full Text] [Related]
15. [The importance and approaches of physicochemical properties analysis of active compounds of traditional Chinese herbs in development of new medicine].
Feng J; Xie P
Zhongguo Zhong Yao Za Zhi; 2003 Sep; 28(9):798-800, 890. PubMed ID: 15015367
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of relative MS response factors of drug metabolites for semi-quantitative assessment of chemical liabilities in drug discovery.
Blanz J; Williams G; Dayer J; Délémonté T; Gertsch W; Ramstein P; Aichholz R; Trunzer M; Pearson D
J Mass Spectrom; 2017 Apr; 52(4):210-217. PubMed ID: 28152561
[TBL] [Abstract][Full Text] [Related]
17. Metabolic profiling of GuanXin II prescription based on metabolic fingerprinting and chemical analysis.
Qiao X; Han J; Xu M; Zhang ZC; Ye M; Ye G; Guo DA
J Pharm Biomed Anal; 2011 Mar; 54(4):789-98. PubMed ID: 21094011
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the physicochemical properties of marketed drugs: can history foretell the future?
Faller B; Ottaviani G; Ertl P; Berellini G; Collis A
Drug Discov Today; 2011 Nov; 16(21-22):976-84. PubMed ID: 21782967
[TBL] [Abstract][Full Text] [Related]
19. Using chiral molecules as an approach to address low-druggability recognition sites.
Lucas X; Günther S
J Comput Chem; 2014 Nov; 35(29):2114-21. PubMed ID: 25223950
[TBL] [Abstract][Full Text] [Related]
20. Working with small molecules: rules-of-thumb of "drug likeness".
Zhang MQ
Methods Mol Biol; 2012; 803():297-307. PubMed ID: 22065233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
